2026 Q2 -tulosraportti
UUTTA
3 päivää sitten
‧42 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 195 | NON | NON | ||
| 500 | NON | DDB | ||
| 3 050 | NRD | DDB | ||
| 833 | NRD | DDB | ||
| 500 | NON | DDB |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 31.8. | ||
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 päivää sittenBut just hold your horses; this is bioTech. It's not about whether the price is 5 or the price is 25. It's about whether the price is 0 or the price is 500+
It takes nothing....when there are neither buyers nor sellers....0.1% of the total number of shares have been traded. Despite the postponement, most are probably just waiting. It can just as quickly go the other way all of a sudden. 😉
·2 päivää sittenReally think it's a good case.. but damn they are bad at communicating.. just an update on how many patients they have treated and a couple of pictures showing uptake.. Just to make investors curious We can easily wait a bit longer.. but honestly, some nice pictures and just an update on treated patients and an indication of what's going on That would also make it easier to raise more money in 27 They change all the time.. new ligand new setup etc.. they should have damn well injected it into a monkey beforehand without mannitol and seen if it was possible..
I don't remember the exact wording from Ulrik, but I got the impression that they have only gotten 6 through so far. The question is whether the next 6 will take just as long.
·2 päivää sitten · MuokattuWhat is happening right now is quite simply...price manipulation...to get cheap shares... Hold onto your shares...
You can call it what you want, perfectly fine. Hard to do it much differently. For months I've been saying the same thing in here and trying to act as a counterweight to the echo chamber of naivety, which potentially causes people to bet more than is good at the wrong time. I currently own approx. 6000 shares in Curasight. A small position compared to before - and it's nicely in profit, which is irrelevant to the matter, as it's not about the here and now regarding that investment. So my actual interest in a fall is limited - I just think it's a shame that many have been buying it expensively over the last couple of months only to wonder about the fall. This is precisely, among other things, because they read extremely naive and absolute best-case scenarios presented here almost as analytical facts. I don't understand why it always has to end there. A forum is NOT for people to agree - and I'm okay with people hating to be told that a stock can both fall and still be good. Other stocks? Yes, definitely. Nanexa is a good place where there's beginning worrying forum activity. It's almost a sell signal for me when you can feel a wave of followers coming in and pushing a stock up too quickly. So, I am currently both invested in that stock and absolutely cautious regarding the desire to act as a counterweight on the forum. I don't need it to rise +200% in 2 days as that creates volatility that moves money from the late-arriving naive follower to the one who knows something about the stock
·3 päivää sittenI didn't really think there was anything new under the sun in today's presentation, more repetitions of what had been said before, with explanations / clarifications of this. They said there is cash in the bank to cover H127, and they hinted / hoped very much that data would come a good while before the end of H127, which makes good sense as some time is needed to raise capital before the cash box runs completely dry. Personally, I wouldn't be surprised if an investor or a group of investors (with good results, of course) comes in H127, which would mean there won't be an issuance before 2028 or later. They explained their reasons for changing the study in uTreat, and why they are more "silent" than shareholders wish them to be; this was due to several factors, such as legislation, competitors, and delivering correct statistical information. They had also added bowel cancer to their basket trial. (it was mentioned very briefly, so hard to know what to make of it). Did anyone else get anything different / more out of the presentation?
I think there are many who question whether the addition of the extra protocol may be due to poor results from the first part of the trial. I think it should be emphasized that it would absolutely not make sense if that were the case. You don't go in and "optimize" and remove a substance that would be beneficial for the medication you are investigating, if the results had been bad. Had the outcome been bad, management would have spent the money investigating and working on one of the other peptides they are developing. Remember that we know Utreat has been seen actively in the tumor 24 after dosing and from preclinical trials the tumor is seen to be kept constant with only 1 dose - and yes there has not been a blood-brain barrier to overcome, but that's just to say: radiation is radiation and if something sits on an object and irradiates for 24 hours, then one can well expect that a good deal can be delivered. Yes, the share price is pointing down with the prospect of results in H1 2027, and an unresolved capital raise. We have to stomach the next couple of months, and forget the share price, but when we get past New Year's, it will probably be fun again 🍻 Good day out there! 😊🔥
·3 päivää sitten · MuokattuThey expect to raise new capital only when they have data from studies. Presumably with capital from a partner. If they were to receive an offer for capital before data becomes available, they would naturally look into it. They cannot publish data now as all patients must first complete the study. Plus there are competitive considerations regarding how much should be published at the current time. Patient enrollment for the prostate study is hopefully completed before Christmas. When they have enough patients for the other study depends on when they receive the new approval.@AlfaRomeo156 : good that you mention the patient recruitment for the prostate study, I forgot that. And what they mentioned about them being delayed by a quarter due to them failing to achieve a specific number of patients in the study within a set date, one must assume that this is part of or the entire explanation for why we haven't seen milestone payment(s) from Curium recently. Edit: it is of course under my assumption that everything is going as expected in the study (apart from the extended patient recruitment).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
3 päivää sitten
‧42 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenBut just hold your horses; this is bioTech. It's not about whether the price is 5 or the price is 25. It's about whether the price is 0 or the price is 500+It takes nothing....when there are neither buyers nor sellers....0.1% of the total number of shares have been traded. Despite the postponement, most are probably just waiting. It can just as quickly go the other way all of a sudden. 😉
- ·2 päivää sittenReally think it's a good case.. but damn they are bad at communicating.. just an update on how many patients they have treated and a couple of pictures showing uptake.. Just to make investors curious We can easily wait a bit longer.. but honestly, some nice pictures and just an update on treated patients and an indication of what's going on That would also make it easier to raise more money in 27 They change all the time.. new ligand new setup etc.. they should have damn well injected it into a monkey beforehand without mannitol and seen if it was possible..I don't remember the exact wording from Ulrik, but I got the impression that they have only gotten 6 through so far. The question is whether the next 6 will take just as long.
- ·2 päivää sitten · MuokattuWhat is happening right now is quite simply...price manipulation...to get cheap shares... Hold onto your shares...You can call it what you want, perfectly fine. Hard to do it much differently. For months I've been saying the same thing in here and trying to act as a counterweight to the echo chamber of naivety, which potentially causes people to bet more than is good at the wrong time. I currently own approx. 6000 shares in Curasight. A small position compared to before - and it's nicely in profit, which is irrelevant to the matter, as it's not about the here and now regarding that investment. So my actual interest in a fall is limited - I just think it's a shame that many have been buying it expensively over the last couple of months only to wonder about the fall. This is precisely, among other things, because they read extremely naive and absolute best-case scenarios presented here almost as analytical facts. I don't understand why it always has to end there. A forum is NOT for people to agree - and I'm okay with people hating to be told that a stock can both fall and still be good. Other stocks? Yes, definitely. Nanexa is a good place where there's beginning worrying forum activity. It's almost a sell signal for me when you can feel a wave of followers coming in and pushing a stock up too quickly. So, I am currently both invested in that stock and absolutely cautious regarding the desire to act as a counterweight on the forum. I don't need it to rise +200% in 2 days as that creates volatility that moves money from the late-arriving naive follower to the one who knows something about the stock
- ·3 päivää sittenI didn't really think there was anything new under the sun in today's presentation, more repetitions of what had been said before, with explanations / clarifications of this. They said there is cash in the bank to cover H127, and they hinted / hoped very much that data would come a good while before the end of H127, which makes good sense as some time is needed to raise capital before the cash box runs completely dry. Personally, I wouldn't be surprised if an investor or a group of investors (with good results, of course) comes in H127, which would mean there won't be an issuance before 2028 or later. They explained their reasons for changing the study in uTreat, and why they are more "silent" than shareholders wish them to be; this was due to several factors, such as legislation, competitors, and delivering correct statistical information. They had also added bowel cancer to their basket trial. (it was mentioned very briefly, so hard to know what to make of it). Did anyone else get anything different / more out of the presentation?I think there are many who question whether the addition of the extra protocol may be due to poor results from the first part of the trial. I think it should be emphasized that it would absolutely not make sense if that were the case. You don't go in and "optimize" and remove a substance that would be beneficial for the medication you are investigating, if the results had been bad. Had the outcome been bad, management would have spent the money investigating and working on one of the other peptides they are developing. Remember that we know Utreat has been seen actively in the tumor 24 after dosing and from preclinical trials the tumor is seen to be kept constant with only 1 dose - and yes there has not been a blood-brain barrier to overcome, but that's just to say: radiation is radiation and if something sits on an object and irradiates for 24 hours, then one can well expect that a good deal can be delivered. Yes, the share price is pointing down with the prospect of results in H1 2027, and an unresolved capital raise. We have to stomach the next couple of months, and forget the share price, but when we get past New Year's, it will probably be fun again 🍻 Good day out there! 😊🔥
- ·3 päivää sitten · MuokattuThey expect to raise new capital only when they have data from studies. Presumably with capital from a partner. If they were to receive an offer for capital before data becomes available, they would naturally look into it. They cannot publish data now as all patients must first complete the study. Plus there are competitive considerations regarding how much should be published at the current time. Patient enrollment for the prostate study is hopefully completed before Christmas. When they have enough patients for the other study depends on when they receive the new approval.@AlfaRomeo156 : good that you mention the patient recruitment for the prostate study, I forgot that. And what they mentioned about them being delayed by a quarter due to them failing to achieve a specific number of patients in the study within a set date, one must assume that this is part of or the entire explanation for why we haven't seen milestone payment(s) from Curium recently. Edit: it is of course under my assumption that everything is going as expected in the study (apart from the extended patient recruitment).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 195 | NON | NON | ||
| 500 | NON | DDB | ||
| 3 050 | NRD | DDB | ||
| 833 | NRD | DDB | ||
| 500 | NON | DDB |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 31.8. | ||
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 -tulosraportti
UUTTA
3 päivää sitten
‧42 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 26.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 31.8. | ||
2026 Q1 -tulosraportti 29.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenBut just hold your horses; this is bioTech. It's not about whether the price is 5 or the price is 25. It's about whether the price is 0 or the price is 500+It takes nothing....when there are neither buyers nor sellers....0.1% of the total number of shares have been traded. Despite the postponement, most are probably just waiting. It can just as quickly go the other way all of a sudden. 😉
- ·2 päivää sittenReally think it's a good case.. but damn they are bad at communicating.. just an update on how many patients they have treated and a couple of pictures showing uptake.. Just to make investors curious We can easily wait a bit longer.. but honestly, some nice pictures and just an update on treated patients and an indication of what's going on That would also make it easier to raise more money in 27 They change all the time.. new ligand new setup etc.. they should have damn well injected it into a monkey beforehand without mannitol and seen if it was possible..I don't remember the exact wording from Ulrik, but I got the impression that they have only gotten 6 through so far. The question is whether the next 6 will take just as long.
- ·2 päivää sitten · MuokattuWhat is happening right now is quite simply...price manipulation...to get cheap shares... Hold onto your shares...You can call it what you want, perfectly fine. Hard to do it much differently. For months I've been saying the same thing in here and trying to act as a counterweight to the echo chamber of naivety, which potentially causes people to bet more than is good at the wrong time. I currently own approx. 6000 shares in Curasight. A small position compared to before - and it's nicely in profit, which is irrelevant to the matter, as it's not about the here and now regarding that investment. So my actual interest in a fall is limited - I just think it's a shame that many have been buying it expensively over the last couple of months only to wonder about the fall. This is precisely, among other things, because they read extremely naive and absolute best-case scenarios presented here almost as analytical facts. I don't understand why it always has to end there. A forum is NOT for people to agree - and I'm okay with people hating to be told that a stock can both fall and still be good. Other stocks? Yes, definitely. Nanexa is a good place where there's beginning worrying forum activity. It's almost a sell signal for me when you can feel a wave of followers coming in and pushing a stock up too quickly. So, I am currently both invested in that stock and absolutely cautious regarding the desire to act as a counterweight on the forum. I don't need it to rise +200% in 2 days as that creates volatility that moves money from the late-arriving naive follower to the one who knows something about the stock
- ·3 päivää sittenI didn't really think there was anything new under the sun in today's presentation, more repetitions of what had been said before, with explanations / clarifications of this. They said there is cash in the bank to cover H127, and they hinted / hoped very much that data would come a good while before the end of H127, which makes good sense as some time is needed to raise capital before the cash box runs completely dry. Personally, I wouldn't be surprised if an investor or a group of investors (with good results, of course) comes in H127, which would mean there won't be an issuance before 2028 or later. They explained their reasons for changing the study in uTreat, and why they are more "silent" than shareholders wish them to be; this was due to several factors, such as legislation, competitors, and delivering correct statistical information. They had also added bowel cancer to their basket trial. (it was mentioned very briefly, so hard to know what to make of it). Did anyone else get anything different / more out of the presentation?I think there are many who question whether the addition of the extra protocol may be due to poor results from the first part of the trial. I think it should be emphasized that it would absolutely not make sense if that were the case. You don't go in and "optimize" and remove a substance that would be beneficial for the medication you are investigating, if the results had been bad. Had the outcome been bad, management would have spent the money investigating and working on one of the other peptides they are developing. Remember that we know Utreat has been seen actively in the tumor 24 after dosing and from preclinical trials the tumor is seen to be kept constant with only 1 dose - and yes there has not been a blood-brain barrier to overcome, but that's just to say: radiation is radiation and if something sits on an object and irradiates for 24 hours, then one can well expect that a good deal can be delivered. Yes, the share price is pointing down with the prospect of results in H1 2027, and an unresolved capital raise. We have to stomach the next couple of months, and forget the share price, but when we get past New Year's, it will probably be fun again 🍻 Good day out there! 😊🔥
- ·3 päivää sitten · MuokattuThey expect to raise new capital only when they have data from studies. Presumably with capital from a partner. If they were to receive an offer for capital before data becomes available, they would naturally look into it. They cannot publish data now as all patients must first complete the study. Plus there are competitive considerations regarding how much should be published at the current time. Patient enrollment for the prostate study is hopefully completed before Christmas. When they have enough patients for the other study depends on when they receive the new approval.@AlfaRomeo156 : good that you mention the patient recruitment for the prostate study, I forgot that. And what they mentioned about them being delayed by a quarter due to them failing to achieve a specific number of patients in the study within a set date, one must assume that this is part of or the entire explanation for why we haven't seen milestone payment(s) from Curium recently. Edit: it is of course under my assumption that everything is going as expected in the study (apart from the extended patient recruitment).
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 195 | NON | NON | ||
| 500 | NON | DDB | ||
| 3 050 | NRD | DDB | ||
| 833 | NRD | DDB | ||
| 500 | NON | DDB |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt